odprn logo ODPRN

Respiratory Reviews

The ODPRN conducted a drug class review on inhaled corticosteroids plus long-acting beta 2-agonists (ICS+LABA) combination products for the management of patients with asthma and chronic obstructive pulmonary disease (COPD), as well as long-acting muscarinic antagonists (LAMAs) for COPD. All three reviews were conducted between November 2013 and April 2015.

Please view the final documents for each review below.

Respiratory Reviews

Reimbursement Option Recommendations
Final Reimbursement Option Recommendations

ICS + LABA for COPD: Final Review Documents

Click to view the complete infographic

Click to view the complete research summary

ICS + LABA for Asthma: Final Review Documents

Click to view the complete infographic

Click to view the complete research summary

LAMAs for COPD: Final Review Documents

Click to view the complete infographic

Click to view the complete research summary

Any questions? Contact us at info@odprn.ca.

Please note that this report is NOT COMPLETE and is still in progress. Click below if you would like to continue.